Wednesday, July 15, 2015
Receptos Acquired By Celgene For $7.2 Billion
San Diego-based Receptos>, a developer of treatments for inflammatory bowel disease and multiple sclerosis, has been acquired by Celgene, in a deal worth $7.2 billion, the two said late Tuesday. According to Celgene, it will pay $232.00 per share in cash for Receptos, to help it accelerate its growth. Celgene said that the acquisition of Receptos "significantly enhances" its Inflammation & Immunology portfolio, and also diversifies the company's revenues.
Get More SocalTech Data
Try our two week free trial to find new tech customers, find high tech startups and jobs, find venture funding, and more!Learn More